In addition, a composite endpoint of hemoglobin A1c (HbA1c) of 7%, no weight gain, and no severe hypoglycemia at 12 weeks were achieved by more patients in the liraglutide group compared to the sulphonylurea group, albeit this did not reach statistical significance (odds ratio (OR) 4.08, 95% confidence interval (CI) 0.97, 17.22, p =0.06). 5.
← all excerpts
Glucagon-Like Peptide-1 (GLP-1) during Ramadan: Narrative Review of the Published Literature.
1
0.0600
0.0600